RT Journal Article
SR Electronic
T1 SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.03.21249162
DO 10.1101/2021.01.03.21249162
A1 Havervall, Sebastian
A1 Falk, August Jernbom
A1 Klingström, Jonas
A1 Ng, Henry
A1 Greilert-Norin, Nina
A1 Gabrielsson, Lena
A1 Salomonsson, Ann-Christin
A1 Isaksson, Eva
A1 Rudberg, Ann-Sofie
A1 Hellström, Cecilia
A1 Andersson, Eni
A1 Olofsson, Jennie
A1 Skoglund, Lovisa
A1 Yousef, Jamil
A1 Pin, Elisa
A1 Christ, Wanda
A1 Olausson, Mikaela
A1 Hedhammar, My
A1 Tegel, Hanna
A1 Mangsbo, Sara
A1 Phillipson, Mia
A1 Månberg, Anna
A1 Hober, Sophia
A1 Nilsson, Peter
A1 Thålin, Charlotte
YR 2021
UL http://medrxiv.org/content/early/2021/04/06/2021.01.03.21249162.abstract
AB Current SARS-CoV-2 serological assays generate discrepant results, and the longitudinal characteristics of antibodies targeting various antigens after asymptomatic to mild COVID-19 are yet to be established. This longitudinal cohort study including 1965 healthcare workers, of which 381 participants exhibited antibodies against the SARS-CoV-2 spike antigen at study inclusion, reveal that these antibodies remain detectable in most participants, 96%, at least four months post infection, despite having had no or mild symptoms. Virus neutralization capacity was confirmed by microneutralization assay in 91% of study participants at least four months post infection. Contrary to antibodies targeting the spike protein, antibodies against the nucleocapsid protein were only detected in 80% of previously anti-nucleocapsid IgG positive healthcare workers. Both anti-spike and anti-nucleocapsid IgG levels were significantly higher in previously hospitalized COVID-19 patients four months post infection than in healthcare workers four months post infection (p=2*10−23 and 2*10−13 respectively). Although the magnitude of humoral response was associated with disease severity, our findings support a durable and functional humoral response after SARS-CoV-2 infection even after no or mild symptoms. We further demonstrate differences in antibody kinetics depending on the antigen, arguing against the use of the nucleocapsid protein as target antigen in population-based SARS-CoV-2 serological surveys.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Region Stockholm, Knut and Alice Wallenberg foundation, Jonas & Christina af Jochnick foundation, Lundblad family foundation, Science for Life Laboratory (SciLifeLab), Erling-Persson family foundation, Svenska Sallskapet for Medicinsk Forskning, Swedish Research Council and CIMED.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Swedish Ethical Review Authority (dnr 2020-01653)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data referred to in the manuscript is available upon reasonable request